Robert F. Kennedy had dinner with Pfizer CEO as he prepares to become health secretary, report says
Pfizer CEO Albert Bourla has revealed that he recently dined with health secretary nominee and vaccine skeptic Robert F. Kennedy Jr. – and vaccine talk was apparently not on the menu.The $150 billion company CEO revealed the pair conversed over a meal after being introduced by President Trump,
Pfizer's CEO says he's had dinner with Trump's health secretary pick, RFK Jr.
Pfizer CEO Albert Bourla said there are "opportunities that probably outweigh the risks" of the Trump administration's "radical" changes.
Pfizer CEO 'Cautiously Optimistic' As RFK Jr. Advances In Senate
CEO Bourla sees "a lot of opportunities that probably outweigh the risks" with the Trump administration, like working together on cancer treatments
Pfizer CEO had dinner with RFK Jr.: ‘I’m cautiously optimistic’ in spite of his history with vaccines
Pfizer shares rose early Tuesday due to higher than expected demand for its COVID vaccine, but quickly sunk 2.3% after Kennedy was confirmed.
Pfizer CEO: Cautiously optimistic on RFK, Jr. HHS secretary nomination
Pfizer CEO Albert Bourla unpacks the impact of the nomination on 'The Claman Countdown.' Some 10 people killed in attack at Swedish school for adults, gunman believed among dead 20 actors who passed on iconic roles Merck shares plunge as company pauses Gardasil vaccine shipments in China,
RFK Jr. 'tempered' his stance on vaccines in private discussions, Pfizer CEO says
Pfizer CEO has met with the new administration and believes Trump and RFK Jr. are going to be net positives for the health sector.
Zepbound sales double, tariffs could hit Ozempic, and Pfizer on RFK Jr.: Pharma news roundup
Sales of Eli Lilly’s (LLY) blockbuster weight-loss drug Zepbound doubled in the fourth quarter year over year, despite ...
Pfizer Falls on RFK’s Progress Towards Confirmation Despite Good Earnings. Its CEO is Unbothered.
CEO Albert Bourla says Pfizer has met the strategic goals it had set for itself in 2024, and that it was ‘executing ...
The faulty forecasts of pharma firm investors: Misguided cynics miss the promising prognosis for drugmakers Pfizer and Merck
Pfizer and Merck, ostensibly beleaguered drugmakers, have seen their shares battered despite reporting strong earnings.
MRNA, PFE, BNTX: Pharma Stocks Fall as RFK Jr. Set to Become U.S. Health Secretary
Shares of vaccine companies such as Moderna (MRNA), Pfizer (PFE) and BioNTech (BNTX), among others, are falling after a ...
Pfizer outlines 2025 R&D milestones and oncology growth opportunities
Bourla outlined 2025 priorities, which include improving R&D productivity, achieving margin expansion, and maintaining commercial excellence. He highlighted expectations for nine Phase 3 readouts, 13 ...
Pfizer shows profit growth from cost cuts and steadier COVID sales
Drugmaker Pfizer posted a better-than-expected fourth-quarter profit on Thursday, helped by cost cuts it began last year as ...
Pfizer CEO: Our stock is very cheap with lots of upside potential
In an interview on CNBC’s Mad Money, Dr. Albert Bourla said Pfizer (PFE) is focusing on business development to create shareholder value. “We ...
Pfizer Q4 Earnings: Solid Results, But Guidance And Patent Concerns Drive The Stock Down
Pfizer's Q4 2024 earnings beat expectations, but concerns over 2025 guidance and patent expirations led to stock decline. See ...
BioSpace3d
Pfizer Eyes Deals up to $15B, With ‘Fruitful’ China Discussions Ongoing
With just one asset in weight loss moving through the clinic, Pfizer targets the space for potential dealmaking, as well as bringing assets over from China.